1. KEI Industries:

This power cable manufacturer surged 11.2% over the past week after Chairman and Managing Director Anil Gupta pointed to a Rs 25,000 crore opportunity arising from India’s expanding data-centre ecosystem.

A February 2026 Deloitte report projects that India could attract nearly $200 billion in data-centre ecosystem investments over the next four years, with installed capacity expected to rise from 1.5 gigawatts in 2025 to up to 10 gigawatts by 2030. Gupta noted that achieving this capacity would require $30–35 billion in core infrastructure capex, fueling huge demand for power cables inside these facilities.

With an estimated 11–13% market share, KEI sees a potential Rs 2,500–3,000 crore revenue opportunity linked to this theme. The company has executed data-centre projects for about five years, although management acknowledged that most assignments so far have been smaller in scale.

On growth visibility, Gupta said, “We expect to grow around 20% overall for the full year and similarly in the next 4-5 years on a CAGR basis.”

Recent results confirm this momentum. In Q3FY26, revenue rose 20.5% YoY, driven by its cables and EPC project businesses. Lower expenses helped net profit soar 42.5%. However, it shows up in a screener of stocks with expensive valuations according to Trendlyne valuation scores.

Despite the bullish outlook, challenges remain. Dependence on the data-centre cycle could expose the company to demand fluctuations and shocks. Volatility in copper and aluminium prices continues to influence margins, and competition is fierce from both domestic and overseas rivals. KEI’s five-year revenue growth of 14.9% lags the industry average of 16.2%, and its market share has recently decreased.

JPMorgan recently began covering KEI Industries with an “overweight” rating and a Rs 5,250 price target. The bank believes KEI outshines its rivals due to its focus on cables (65–70% of revenue), a superior product mix, robust exports, and its emphasis on Extra High Voltage products.

2. Astra Microwave Products:

The stock of this aerospace & defence company rose by over 6% in the past week following robust Q3 results and a bullish growth outlook. The Indian defence sector continues to gain momentum from the government's indigenization push, further strengthened by the Union Budget 2026–27, which allocated Rs 7.9 lakh crore to the Ministry of Defence, a 15.2% annual increase. With Rs 1.4 lakh crore earmarked for domestic procurement, investor interest in local defence manufacturers remains exceptionally high.

Quarterly revenue rose 19.6% sequentially to Rs 261.6 crore, driven by strong order inflows in the defense and metrology segments. Meanwhile, net profit saw a 87.7% surge to Rs 38.9 crore. It appears in a screener of stocks that have shown relative outperformance versus the industry over the past month.

The company’s net profit beat Trendlyne’s Forecaster estimates substantially, by 53.5% due to a strategic shift toward a more profitable product mix. Q3 order inflows reached Rs 470 crore, with another Rs 500–600 crore anticipated in the final quarter. By pivoting away from low-margin export contracts and toward high-margin, design-led business, Astra has successfully built an export order book currently valued at Rs 130 crore.

MD SG Reddy reaffirmed the company's growth targets, stating, “We are confident on reaching our Rs 1,150 crore revenue target for the year... and are on track for 15% growth in FY27 with an order book of over Rs 1,500 crore.” This guidance suggests a steady near-term trajectory as the company scales its operations to meet rising domestic and international demand for specialized aerospace components.

Management expects to double revenues over the next four years, with the most significant gains appearing from FY28 onwards. This expansion will be fueled by technological milestones, including the Quick Reaction Surface-to-Air Missile (QRSAM) execution in FY27, the Uttam AESA radar in FY28, and the Su-30 Virupaksha radar in FY29. These high-tech defense and space segments are expected to further boost operating margins as they move into full-scale production cycles.

Motilal Oswal maintained its ‘Buy’ rating with a raised target of Rs 1,150, noting Astra’s prime position to tap a Rs 25,000 crore addressable market over the next five years. Growth is expected from DRDO and PSU orders for the QRSAM, Tejas, and Su-30 platforms. Furthermore, the Astra-Rafael joint venture holds a robust $80 million order book, with $18.2 million executed in Q3, reinforcing a sustainable growth trajectory for the next six years.

3. Schaeffler India: 

This ball bearing manufacturer surged 14% over the past week after reporting its Q4FY25 results. Revenue rose 28% YoY, while net profit increased 36%. Both metrics beat Forecaster estimates by a wide margin, supported by growth in the automotive vertical. The firm appeared in a screener of companies delivering the best results last week.

The firm gets around 40% of revenue from its bearings business. Automotive technologies, which contribute roughly 35% to total sales, grew 42% during the quarter. Growth was driven by auto demand, new business wins, and improved domestic momentum following GST rationalisation. The rest of the revenue comes from selling replacement parts and exports to its German parent, Schaeffler AG.

Operational efficiency improved during the quarter. EBITDA margin expanded by 43 basis points, aided by a higher share of locally manufactured components. Capacity utilisation crossed 85% last quarter, further bringing down unit costs.

Looking ahead, the company plans to invest Rs 500 crore in capex in 2026 to support localisation and meet rising automotive and industrial demand. CFO Hardevi Vazirani said the company “intentionally slowed down spending in 2025 to focus on capacity utilisation and capital efficiency.” She added that capex will now accelerate, as the firm looks to enhance backward integration and manufacturing capabilities under its five-year investment plan.

In September last year, the company announced a Rs 4,500 crore investment roadmap through 2030 aimed at strengthening capacity and expanding its product portfolio.

Analysts maintain a ‘Buy’ consensus on the stock, with a target price of Rs 4,710. They expect revenue and net profit to grow at a CAGR of 11% and 17%, respectively, through 2027. Trendlyne data indicates the stock may be undervalued by about 24% based on its projected earnings trajectory.

4. Hindustan Unilever (HUL):

This personal products giant’s stock price climbed 2.6% over the past week after its board of directors approved a Rs 2,000 crore investment plan over the next two years. HUL will use these funds to boost manufacturing capacity for fast-growing premium products in beauty, wellbeing, and home care. This move targets high-demand areas like skin care, hair care, and liquid detergents.

Earlier this month, HUL reported its Q3FY26 results. Revenue rose 3.3% YoY, driven by robust demand across home care, beauty, and food segments, aided by lower GST rates. Meanwhile, net profit soared 121.4%. A richer product mix and one-time gains from the ice cream business demerger and acquisitions of Oziva and Minimalist fueled this surge.

The home care segment grew in the mid-single digits, led by fabric wash and liquids. Management noted that liquids offer significant growth potential, as it currently accounts for just 7% of the overall detergent market in India. The beauty and wellbeing segment expanded in double digits, supported by the scale-up of Minimalist and Oziva. 

Buoyed by these results, CFO & Executive Director Niranjan Gupta said, “We retain our EBITDA margin guidance at 22-23% for FY27, led by a low-single-digit hike in prices.” He added that revenue growth in FY27 should outperform FY26, driven by improving urban and rural demand, coupled with easing inflation.

Following these developments, Motilal Oswal retained a ‘Buy’ rating with a target price of Rs 2,800, implying a 19.8% upside. The brokerage believes the company is well-positioned to achieve volume growth through capacity expansions and favourable economic trends. Analysts expect HUL to deliver annual revenue growth of 7% with profit growth of 10% through FY28.

5. Biocon:

This biotechnology firm rose 2% in the last week as it secured US FDA approval for its Liraglutide injection. Liraglutide is used for weight loss and blood sugar control. 

According to NCBI data, patients on liraglutide achieved at least 5% weight loss compared with those given an inactive treatment. While it’s not as effective as newer GLP-1 drugs like Tirzepatide (~20% weight loss) and Semaglutide (~15%), it is preferred by cost-conscious patients. According to IQVIA, the US market recorded approximately $127 million in sales in 2025.

In Q3FY26, revenue grew 9% YoY to Rs 4,173 crore. The biosimilars segment, which are lower-cost alternatives to large, complex drugs, grew about 9%. This contributed to 61% of revenue, driven by market share gains and recent launches. Generics, which are lower-cost versions of branded drugs sold after patents expire, grew 24%. This was led by strong Liraglutide demand in Europe and improved traction in the US generics business. Research services declined 3%, partly offsetting gains from the drug businesses.

Net profit surged 475%, driven by margin expansion and a low base. EBITDA margins expanded by 30 bps to 22%. Biosimilars margins stood at around 28%, aided by a greater share of regulated market sales. North America accounted for 46% of biosimilars revenue during the quarter, a favourable mix given the region’s better pricing and profitability.

The company reduced net debt by 16% from FY23 levels, lowering finance costs. “Interest cost has already started coming down, and we should see annualized savings of approximately Rs 300 crore from FY27,” said Executive Chairperson Kiran Mazumdar Shaw.

Shreehas Tambe, CEO & MD of Biocon Biologics, noted that biosimilars margins improved as the company “prioritized supply toward higher-margin markets,” and stated that margins should “normalize toward the mid-20% range going forward.” He added that more Liraglutide launches are planned in the US and Latin America over the next few quarters.

Axis Securities reiterated its ‘Buy’ rating with a lower target price of Rs 435, citing reduced earnings estimates after quarterly revenue and margins fell short of expectations. The brokerage maintained that biosimilars and generics remain the primary growth drivers, while lower capital spending and declining interest costs are expected to support margin improvement.

Trendlyne's analysts identify stocks that are seeing interesting price movements, analyst calls, or new developments. These are not buy recommendations.